J&J gets FDA breakthrough therapy status for nipocalimab in Sjogren's

Iryna Drozd Johnson & Johnson ( NYSE: JNJ ) has received FDA breakthrough therapy designation for its drug candidate nipocalimab in the treatment of moderate-to-severe Sjogren’s disease. The FDA also granted breakthrough therapy designation to nipocalimab earlier this year for hemolytic disease of the fetus.